≥99%HPLC Purity
COAIncluded
USAShipped
CJC-1295 (no DAC) Peptide
Modified Growth Hormone Releasing Hormone analog without Drug Affinity Complex. 30-amino acid GHRH analog with enhanced receptor affinity.
Coming Soon
This compound is currently in our development pipeline. Enter your email to be notified when it becomes available for research purchase.
Quick Facts
| SKU | ACR-CJC1295 |
|---|---|
| CAS Number | 863288-34-0 |
| Molecular Weight | 3367.97 g/mol |
| Sequence | 30-amino acid GHRH analog |
| Purity | ≥98% |
| Physical Form | Lyophilized Powder |
| Storage | Store at -20°C |
What is CJC-1295 (no DAC)?
CJC-1295 without DAC, also known as Modified GRF (1-29) or Mod GRF 1-29, is a synthetic 30-amino acid analog of growth hormone releasing hormone (GHRH). It contains four amino acid substitutions at positions 2, 8, 15, and 27 compared to native GHRH(1-29), specifically designed to improve metabolic stability and resist enzymatic degradation by DPP-IV.
Unlike the DAC (Drug Affinity Complex) variant, this version lacks the maleimidopropionic acid-lysine conjugation that enables albumin binding. This results in a shorter pharmacokinetic profile with more pulsatile receptor activation, which more closely mimics natural GHRH secretion patterns.
For laboratory research use only.
Mechanism of Action
GHRH Receptor Activation
CJC-1295 binds to the growth hormone releasing hormone receptor (GHRHR), a class B G-protein coupled receptor expressed on anterior pituitary somatotroph cells. Receptor activation stimulates Gs-protein coupling, adenylyl cyclase activation, and cAMP production, leading to PKA-mediated GH gene transcription and GH secretion.
Pulsatile vs Sustained Release
The no-DAC variant produces pulsatile GHRH receptor activation due to its shorter half-life (approximately 30 minutes vs 8+ days for the DAC version). This pulsatile pattern is significant because natural GH secretion is pulsatile, and sustained GHRH receptor activation can lead to receptor desensitization.
Synergy with GHS-R1a Agonists
Research has documented synergistic effects when CJC-1295 no DAC is combined with GHS-R1a agonists like Ipamorelin. The GHRH receptor and ghrelin receptor signal through complementary pathways that converge on somatotroph cells, amplifying GH release beyond additive effects.
Mechanism of Action
CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF) is a 29-amino acid analog of GHRH(1-29) with four amino acid substitutions (Ala2→D-Ala, Asn8→Gln, Ala15→Ala(modified), Met27→Leu) that confer resistance to DPP-4 and other proteases. The mechanism:
- GHRH-R binding: CJC-1295 binds the GHRH receptor on anterior pituitary somatotrophs with similar affinity to native GHRH
- cAMP/PKA activation: GHRH-R is a Gs-coupled GPCR. Binding activates adenylyl cyclase → cAMP → PKA → CREB phosphorylation → GH gene transcription and vesicle exocytosis
- Pulsatile release: Unlike DAC version, Mod GRF produces a discrete GH pulse lasting 30-60 minutes, mimicking physiological GHRH signaling
- Somatostatin interaction: The short half-life allows normal somatostatin suppression between pulses, preserving the natural GHRH-somatostatin oscillation that regulates GH pulsatility
Research & Clinical Studies
CJC-1295 No DAC vs DAC: Comparative Research
CJC-1295 without DAC (Modified GRF 1-29) has a half-life of approximately 30 minutes compared to 6-8 days for the DAC version. This shorter duration produces discrete, physiological GH pulses rather than sustained elevation. Research comparing the two found: no-DAC produces sharper but shorter GH peaks (more physiological), no-DAC has lower IGF-1 elevation but more natural pulsatility, no-DAC requires more frequent dosing but avoids the continuous GH "bleed" effect of DAC.
Many researchers prefer the no-DAC version precisely because it better mimics natural GHRH signaling — a brief pulse followed by return to baseline, allowing the somatostatin-GHRH interplay to continue normally.
Combination with Ipamorelin
The CJC-1295/Ipamorelin combination is the most widely researched GH secretagogue stack. CJC-1295 (GHRH analog) amplifies the GH pulse amplitude, while Ipamorelin (ghrelin receptor agonist) increases pulse frequency. Together, they produce synergistic GH elevation greater than either alone — typically 3-5x baseline vs 2-3x individually. The combination also avoids cortisol and prolactin increases seen with less selective GHRP compounds.
Research: GH Pulse Characteristics
Pharmacokinetic studies of CJC-1295 no DAC demonstrate GH pulse characteristics that closely resemble endogenous GHRH signaling:
- Peak GH: 2-3x baseline within 15-30 minutes of administration
- Duration: GH returns to baseline within 60-90 minutes
- IGF-1: Modest, transient IGF-1 elevation (unlike DAC version which sustains IGF-1 for days)
- Cortisol: No significant cortisol increase (unlike GHRP-6 or Hexarelin)
- Prolactin: No prolactin increase (unlike GHRP-6)
This clean GH pulse profile — GH up, cortisol and prolactin unaffected — is why Mod GRF is considered the most selective GHRH analog for research. When combined with Ipamorelin (equally selective ghrelin agonist), the pair produces the purest GH signal available from peptide secretagogues.
Chemical Properties
| Full Name | CJC-1295 without DAC (Modified GRF 1-29, Mod GRF) |
|---|---|
| Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ |
| Amino Acids | 29 (GHRH 1-29 analog) |
| Key Modifications | Ala2→D-Ala, Asn8→Gln, Ala15→Ala, Met27→Leu |
| Half-life | ~30 minutes (vs ~7 minutes for native GHRH) |
| Receptor | GHRH-R (Gs-coupled GPCR on somatotrophs) |
| Purity | ≥98% HPLC |
Storage & Stability
Lyophilized: -20°C for 24 months, 2-8°C for 6 months. Reconstituted: 2-8°C, use within 14 days. Mod GRF is a 29-amino acid peptide — more degradation-prone than shorter peptides. The D-Ala2 and Leu27 substitutions provide 4x longer half-life than native GHRH but it remains sensitive to heat and oxidation.
Frequently Asked Questions
What is CJC-1295 no DAC?
CJC-1295 without DAC (Modified GRF 1-29) is a synthetic 30-amino acid GHRH analog with four stabilizing amino acid substitutions. It activates the GHRH receptor on pituitary somatotroph cells. The no-DAC version has a shorter duration than the DAC variant.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC has a Drug Affinity Complex that binds albumin, extending its half-life to 8+ days for sustained GHRH receptor activation. The no-DAC version has a ~30 minute half-life, producing pulsatile stimulation that more closely mimics natural GHRH secretion patterns.
Why combine CJC-1295 no DAC with Ipamorelin?
They target complementary receptors: CJC-1295 activates GHRH receptors while Ipamorelin activates GHS-R1a (ghrelin) receptors. Both receptors are expressed on pituitary somatotroph cells and signal through different but convergent pathways, producing synergistic GH release.
CJC-1295 no DAC vs with DAC?
No DAC: ~30 min half-life, produces natural GH pulses, requires frequent dosing. With DAC: ~6-8 day half-life, sustained GH elevation, once-weekly. No DAC is preferred for protocols mimicking physiological GHRH signaling; DAC for sustained IGF-1 elevation.
Why combine CJC-1295 with Ipamorelin?
They target different receptors (GHRH-R vs GHS-R1a) and produce synergistic GH release. CJC-1295 amplifies pulse amplitude, Ipamorelin increases frequency. The combination is selective — no cortisol/prolactin increase unlike GHRP-6 or Hexarelin.
What does "Modified GRF 1-29" mean?
GRF = Growth hormone Releasing Factor (synonym for GHRH). 1-29 = first 29 amino acids (the bioactive fragment). "Modified" = four amino acid substitutions for protease resistance. CJC-1295 no DAC, Mod GRF 1-29, and tesamorelin analog all refer to this compound.
How often should CJC-1295 no DAC be administered in research?
Due to its ~30-minute half-life, Mod GRF is typically dosed 2-3x daily in research protocols (mimicking natural GHRH pulse timing). Common timing: upon waking, post-exercise, and before sleep — aligning with physiological GH release windows.
For laboratory and research use only. Not intended for human or animal consumption. All product information is derived from published preclinical research and does not constitute medical advice or claims.